Trial Type
First-Line-Therapy (Metastatic Disease/Hematology)
Description for experts
IDE196 (Darovasertib) in combination with Crizitinib versus Investigator´s Choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma
Description for laymen
JSON Data
{
"short_title": "IDE196-002",
"data_mode": "900",
"data_mode_number": "000002435",
"official_title": "IDE196 (Darovasertib) in combination with Crizitinib versus Investigator\u00b4s Choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma",
"accrual_state": "running",
"therapeutic_value": "therapeutic",
"therapieansatz_value": "palliativ",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "first",
"ctgov_number": null,
"eudract_number": "2023-506686-66",
"general_contact_email": "oncostudien.dermatologie@ukdd.de",
"general_contact_phone": "+49 351-45819782",
"hauptpruefer_dd_name": "Prof. Dr. med. Friedegund Meier",
"description_laie_de": "IDE196 (Darovasertib) in Kombination mit Crizotinib gegen\u00fcber der vom Pr\u00fcfarzt gew\u00e4hlten Behandlung als Erstlinientherapie bei HLA-A2-negativem metastasiertem Aderhautmelanom (DAR-UM-2)",
"description_laie_en": null,
"description_expert_de": null,
"description_expert_en": "IDE196 (Darovasertib) in combination with Crizitinib versus Investigator\u00b4s Choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma",
"rechtsgrundlage_value": "AMG",
"phase_amg_value": "II_III",
"main_cat_id": 5,
"sub_cat_id": 32
}
